OOIR: Observatory of International Research

Papers

(The H4-Index of Lupus Science & Medicine is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field	209
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol	57
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus	43
Genetic load in incomplete lupus erythematosus	43
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	42
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease	42
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis	40
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus	39
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children	35
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases	34
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort	34
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	32
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	29
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance	28
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus	27
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus	26
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial	25
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	24
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory	23
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	22
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials	22
Canadian workplace experiences of systemic lupus erythematosus (SLE)	21